A phase 2 study evaluating dose dense AC (ddAC) followed by dose dense paclitaxel (ddP) supported by 3.6 mg peg-filgrastim (ddAC-ddP3.6) for patients (pts) with primary breast cancer (PBC) in Japan -WJOG9016B-. (March 2019) - Matsumoto, K.; Futamura, M.; Miyaki, T.; Iwasa, T.; Imoto, S.; Doi, M.; Tokunaga, S.; Aogi, K.; Yoshimura, K.; Takano, T.; ,